Ketamine Infusions Fail to Outperform Placebo in New Depression Trial

A recent clinical trial, **KARMA-Dep 2**, found that repeated **ketamine** infusions offered no meaningful advantage over an active **placebo** for **depression** patients. Both groups saw mood improvements, but adjusted analyses failed to show a clinically meaningful difference. The study's real-world design showed **ketamine** to be generally safe but not superior. Researchers conclude that **ketamine's** antidepressant reputation might be overstated. The trial, published in **JAMA Psychiatry**, compared eight twice-weekly infusions of **ketamine** to a similar **midazolam** schedule. Among 65 participants, both groups enjoyed measurable mood improvements, but **ketamine** failed to display a statistical edge. The study's findings have significant implications for the treatment of **depression**, particularly in patients who have not responded to traditional therapies. [[ketamine|Ketamine]] has been hailed as a potential breakthrough treatment for **depression**, but this study suggests that its effectiveness may be overstated. [[depression|Depression]] is a complex and multifaceted condition, and treatment options are often limited. The **KARMA-Dep 2** study highlights the need for further research into the effectiveness of **ketamine** and other potential treatments for **depression**.

• The **KARMA-Dep 2** study found that repeated **ketamine** infusions offered no meaningful advantage over an active **placebo** for **depression** patients
• The study compared eight twice-weekly infusions of **ketamine** to a similar **midazolam** schedule
• Among 65 participants, both groups enjoyed measurable mood improvements, but **ketamine** failed to display a statistical edge
• The study's findings have significant implications for the treatment of **depression**, particularly in patients who have not responded to traditional therapies
• Further research is needed to fully understand the effectiveness of **ketamine** and other potential treatments for **depression**

The **KARMA-Dep 2** study's findings are a reminder that **depression** is a complex and multifaceted condition, and that treatment options are often limited. The study's use of an active **placebo** and a real-world design adds to the study's validity, but the results are not conclusive. [[ketamine|Ketamine]] may still have a role to play in the treatment of **depression**, but further research is needed to fully understand its effectiveness. The study's findings highlight the need for continued research into the effectiveness of **ketamine** and other potential treatments for **depression**. [[clinical-trials|Clinical trials]] like the **KARMA-Dep 2** study are essential for advancing our understanding of **depression** and developing effective treatments.

The **KARMA-Dep 2** study's findings may be disappointing, but they also highlight the need for further research into the effectiveness of **ketamine** and other potential treatments for **depression**. The study's use of an active **placebo** and a real-world design adds to the study's validity, and the results have significant implications for the treatment of **depression**. [[ketamine|Ketamine]] may still have a role to play in the treatment of **depression**, particularly in patients who have not responded to traditional therapies. Further research is needed to fully understand the effectiveness of **ketamine** and to develop more effective treatments for **depression**. [[mental-health|Mental health]] professionals will need to carefully consider the study's findings when developing treatment plans for patients with **depression**.

The **KARMA-Dep 2** study's findings are a significant setback for the treatment of **depression**. The study's use of an active **placebo** and a real-world design adds to the study's validity, but the results suggest that **ketamine** may not be as effective as previously thought. [[ketamine|Ketamine]] may not have a significant role to play in the treatment of **depression**, and the study's findings highlight the need for a re-evaluation of current treatment options. The study's authors suggest that **ketamine's** antidepressant reputation may be overstated, and that further research is needed to fully understand its effectiveness. [[mental-health|Mental health]] professionals will need to carefully consider the study's findings when developing treatment plans for patients with **depression**.

Originally reported by Psychiatrist.com